Clinical Trial Update: Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of docetaxel in patients with recurrent or refractory ovarian cancer or primary peritoneal cancer; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: TERMINATED